19:15 , Jul 19, 2019 |  BC Extra  |  Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Ahead of Vascepa push, Amarin adds $400M to coffers  With the Sept. 28 PDUFA date looming for a potential expansion of the label for Vascepa icosapent to include reduced cardiovascular risk, Amarin Corp. plc (NASDAQ:AMRN)...
21:22 , Jul 2, 2019 |  BC Extra  |  Financial News

July 2 Financial Quick Takes: Suspension continues for Woodford fund; plus CRUK, Codiak and Amarin

Woodford extends fund suspension  Woodford Investment Management Ltd. extended to July 29 the suspension of trading in its flagship fund, Woodford Equity Income Fund. The extension’s purpose is to allow the fund manager more time...
01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
21:41 , May 29, 2019 |  BC Extra  |  Company News

May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk  Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted Priority Review to an sNDA for Vascepa icosapent ethyl to reduce...
13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

Amarin reported additional data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) showing that the drug led to a 30% reduction in total CV events vs....
04:32 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million on Nov. 26 in a follow-on as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase...
18:57 , Nov 27, 2018 |  BC Extra  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million in a follow-on late Monday as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase III...
16:04 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Amarin details primary endpoint data for Vascepa, addresses placebo concern

Amarin Corp. plc. (NASDAQ:AMRN) presented detailed primary endpoint data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) and addressed concerns that the mineral oil used in...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...